New Market Report Now Available: Indonesia Pharmaceuticals & Healthcare Report Q4 2010

Sept. 15, 2010 - PRLog -- In BMI's Business Environment Rating matrix for Q410, we see Indonesia occupying 11th place, out of the 17 regional markets surveyed in the Asia Pacific region. The country's pharmaceutical rating has risen to 48.9, marking a slight increase over the previous quarter. However, it is still lower than the average for the region, which stands at 52.3. The main drawbacks to investment in Indonesia include corruption, low per-capita spending on pharmaceuticals and a small proportion of the elderly in the country. On the other hand, factors such annual growth of its pharmaceutical market, coupled with rising population numbers and a relatively solid political and economic base are expected to encourage multinationals to invest in the country despite a risky operating environment. We therefore envisage that sales of pharmaceutical products will increase over the next 10 years, with sales of prescription drugs and over-the-counter (OTC) medicines expected to grow from US$2.92bn in 2009 to US$5.89bn in 2014 and US$11.00bn in 2019, thus representing compound annual growth rates (CAGRs) in local currency terms of 10.86% and 10.84% for 2009-14 and 2014-19 respectively.

The head of Indonesia's investment-coordinating board recently announced that efforts will be made to open more sectors to overseas investment - including health and agriculture, but not dealing with areas such as telecommunication towers for mobile telephones. To this end, a draft proposal citing investment in strategic areas, known as the negative list on foreign investment, has already been finalised and is expected to be approved soon.

Elsewhere, recent findings suggest that most people suffering from bleeding disorders in the country are not properly diagnosed and therefore fail to receive proper treatment for the disease. It is thought that only 5% of cases in Indonesia have so far been successfully diagnosed. It is estimated that there are approximately 20,000 haemophiliacs across the country, with only 1,200 being registered as of March 2010.

Meanwhile, Singapore-based Invida Group, a leading specialty biopharmaceutical company announced that it has completed a joint venture agreement with domestic pharmaceutical manufacturer PT MUGI Laboratories. Under the terms of the agreement, Invida will seek to expand its operations in Indonesia to include: the importation of raw materials and auxiliaries; the possession of regulatory licenses for the manufacture of pharmaceutical products; the provision of toll manufacturing support; and providing marketing expertise throughout the archipelago.

In other developments, PT Bio Farma announced that it is to spend IDR500bn (US$55mn) on a facility to produce blood plasma products, including albumin and Factor IX. The plant will be the first of its kind in Indonesia and will be built using assistance from South Korean and Australian pharmaceutical companies, based on guidelines stipulated by the WHO. Indonesia is the world's fourth most populous country but currently has to import the majority of its blood plasma products, primarily from the Netherlands.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/83382_indonesia_pharmaceutical...

Partial Table of Contents:

Executive Summary
SWOT Analysis
- Indonesia Pharmaceutical And Healthcare Industry SWOT
- Indonesia Political SWOT
- Indonesia Economic SWOT
- Indonesia Business Environment SWOT
Pharmaceutical Business Environment Rating
- Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q410
- Limits of Potential Returns
- Risks to Realisation of Returns
Market Summary - Indonesia
Regulatory Regime
- Intellectual Property Issues
- Generic Drug Legislation
- Labelling Requirements
- Counterfeit and Substandard Drugs
- Free Trade Agreements
- Pricing Regime
- Price Cuts
- Reimbursement Regime
Industry Trends and Developments
- Epidemiology
- Recent Public Health Developments
- Table: UN Millennium Development Goals
- Avian and Swine Flu
- International Avian Flu Partnerships
- Healthcare System
- Healthcare System Reform
- International Healthcare Collaborations
- Pharmaceutical Retail Sector
- Research and Development
- Herbal Medicines
- Medical Devices
Industry Forecast Scenario
- Overall Market Forecast
- Key Growth Factors - Industry
- Key Growth Factors - Macroeconomic
- Table: Indonesia - Economic Activity
- Prescription Drug Market Forecast
- Patented Drug Market Forecast
- Generic Drug Market Forecast
- OTC Medicine Market Forecast
- Medical Device Market Forecast
- Pharmaceutical Trade Forecast
- Other Healthcare Data and Forecasts
- Key Risks to BMI's Forecast Scenario
Competitive Landscape
- Pharmaceutical Sector
- Domestic Industry
- Foreign Industry
- Recent Pharmaceutical Sector Developments
Company Profiles
- Indigenous Manufacturers
- PT Kalbe Farma
- PT Bio Farma
- Kimia Farma
- PT Sido Muncul
- Combiphar PT
- Leading Foreign Manufacturers
- Sanofi-Aventis
- Pfizer
- Novartis
- GlaxoSmithKline (GSK)
- Merck & Co
- Bayer
Country Snapshot: Indonesia Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2000-2005
- Table: Vital Statistics, 2005-2030
-

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=8338...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.